AstraZeneca Launches Major CAMBRIA Trials Investigating Camizestrant for Early-Stage ER-Positive Breast Cancer

Camizestrant: A New Generation Hormonal Therapy

AstraZeneca has initiated two global Phase III trials—CAMBRIA-1 and CAMBRIA-2—to evaluate camizestrant, a next-generation selective estrogen receptor degrader (ngSERD), in preventing recurrence in patients with early-stage estrogen receptor (ER)-positive, HER2-negative breast cancer. While current standard care with endocrine therapies (such as tamoxifen or aromatase inhibitors) significantly lowers recurrence risk, many patients at intermediate or high risk still experience disease return, often years after treatment, underscoring the need for more effective options.

Camizestrant, unlike current therapies, both blocks and degrades the estrogen receptor, inhibiting tumor growth by a distinct mechanism of action. Prior studies in advanced breast cancer have shown camizestrant to outperform the existing SERD, fulvestrant, in delaying disease progression and reducing hormone receptor activity within tumors.

Promising Early Results

Although results from CAMBRIA-1 and CAMBRIA-2 are pending, prior trials provide a strong foundation: in advanced settings, camizestrant improved progression-free survival and demonstrated substantial tumor ER reduction, supporting its selection for these large adjuvant studies. CAMBRIA-1 will assess camizestrant in patients who have completed surgery and 2–5 years of endocrine therapy, while CAMBRIA-2 is focused on patients with minimal prior endocrine therapy post-surgery. Both studies aim to determine if camizestrant can further extend the duration patients remain cancer-free versus existing standard treatments.

The two trials are recruiting approximately 9,800 participants in total, across more than 1,300 sites globally. Key clinical endpoints include invasive breast cancer-free survival and distant recurrence-free survival, alongside overall survival, safety, and patient-reported outcomes.

What’s Next for AstraZeneca?

Pending results from these pivotal trials, AstraZeneca is poised to redefine endocrine therapy management in early breast cancer if camizestrant proves superior to standard care. Positive findings could catalyze regulatory submissions and accelerate efforts to expand treatment options to patients at greatest risk for recurrence. The company will closely monitor safety, efficacy, and patient quality-of-life measures during these studies, with interim analyses planned to guide future clinical and business strategies.

In summary, the CAMBRIA studies represent a significant push to address the longstanding unmet need for more durable adjuvant endocrine therapy in ER-positive early breast cancer, potentially establishing camizestrant as a new standard of care.